EcoDrugPlus

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSSFOG00015019314
Gene Symbol: PARP3
3 Cross references
199 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSSFOG00015000133
Gene Symbol: PORCN
3 Cross references
197 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSSFOG00015014902
Gene Symbol: KCNMA1
1 Cross references
161 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSSFOG00015017046
Gene Symbol: KCNN4
3 Cross references
187 Possible Orthologues:

Potassium Channel, Subfamily K, Member 2b

Ensembl ID : ENSSFOG00015020640
Gene Symbol: KCNK2B
1 Cross references
213 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSSFOG00015025143
Gene Symbol: KCNJ11
3 Cross references
188 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSSFOG00015007898
Gene Symbol: KCNJ2
3 Cross references
202 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSSFOG00015028713
Gene Symbol: KCNJ3
3 Cross references
224 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSSFOG00015026200
Gene Symbol: KCNJ3
3 Cross references
224 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSSFOG00015008783
Gene Symbol: KCNJ5
3 Cross references
202 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSSFOG00015022315
Gene Symbol: KCNJ5
1 Cross references
133 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSSFOG00015017981
Gene Symbol: KCNK2
1 Cross references
161 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).